Cases Methotrexate pneumonitis in a patient with gestational trophoblastic neoplasia

Article Sidebar

PDF HTML
Published: 2022-10-04
DOI: https://doi.org/10.7196/AJTCCM.2022.v28i3.254

Main Article Content

M Agarwal
Department of Pulmonary Medicine, Eternal Hospital Care Center, Jaipur, Rajasthan, India
K K Sharma
Department of Pulmonary Medicine, Eternal Hospital Care Center, Jaipur, Rajasthan, India
K Deokar
Department of Pulmonary Medicine, Sapphire Hospitals, Thane, Maharashtra, India
N Bharti
Department of Anaesthesiology and Critical Care, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India

Abstract





Methotrexate, an immunomodulatory agent used for a wide variety of indications, can cause pulmonary toxicity in the form of pneumonitis, organising pneumonia, pulmonary fibrosis, pleural effusion, pulmonary infections or lymphoproliferative disease. We report a case of methotrexate pneumonitis in a patient with gestational trophoblastic neoplasia. The diagnosis of methotrexate pneumonitis is challenging, as the signs and symptoms can be caused by intercurrent infection, concomitant medications or an underlying disease condition. A high index of suspicion is required for diagnosis. Management consists of drug discontinuation and steroids in patients with respiratory failure.





Downloads

Download data is not yet available.

Article Details

Issue

AJTCCM Vol. 28 No. 3

Section

Correspondence
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors retain copyright and grant the journal right of first publication.

How to Cite

1.
Agarwal M, Sharma KK, Deokar K, Bharti N. Cases: Methotrexate pneumonitis in a patient with gestational trophoblastic neoplasia. Afr J Thoracic Crit Care Med [Internet]. 2022 Oct. 4 [cited 2026 Apr. 27];28(3):133-4. Available from: https://samajournals.co.za/index.php/ajtccm/article/view/249

References

Jakubovic BD, Donovan A, Webster PM, Shear NH. Methotrexate-induced pulmonary toxicity. Can Respir J 2013;20(3):153-155. https://doi. org/10.1155/2013/527912

Chhabra P, Law AD, Suri V, Malhotra P, Varma S. Methotrexate induced lung injury in a patient with primary CNS lymphoma: A case report. Mediterr J Hematol Infect Dis 2012;4(1):e2012020. https://doi. org/10.4084/MJHID.2012.020

Salehi M, Miller R, Khaing M. Methotrexate-induced hypersensitivity pneumonitis appearing after 30 years of use: A case report. J Med Case Rep 2017;11(1):174. https://doi.org/10.1186/s13256-017-1333-0

Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: Review of the literature and histopathological findings in nine patients. Eur Respir J 2000;15(2):373-381. https://doi.org/10.1034/ j.1399-3003.2000.15b25.x

SearlesG,McKendryRJ.Methotrexatepneumonitisin rheumatoid arthritis: Potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987;14(6):1164-1171.

Barrera P, Laan RFJM, van Reil PLCM, Dekhuijen PNR, Boerbooms AMTh, van de Putte LBA. Methotrexate related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994;53(7):434- 439. https://doi.org/10.1136/ard.53.7.434

Gillespie AM, Lorigan PC, Radstone CR, Waterhouse JC, Coleman RE, Hancock BW. Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate. Br J Cancer 1997;76(10):1382- 1386. https://doi.org/10.1038/bjc.1997.564

Zhang D, Ding Z, Qian J, Xie X, Wang Y. Two rare cases of methotrexate-induced pneumonitis and pleurisy in patients with gestational trophoblastic neoplasms. Eur J Gynaecol Oncol 2008;29(4):390-392.